Piet Ost, MD, PhD, Ghent University, Ghent, Belgium, discusses the findings of a meta-analysis of data from four trials investigating the safety and clinical benefit of metastasis-directed therapy for oligorecurrent prostate cancer. Data from 174 patients, 72% of whom received metastasis-directed therapy and 28% of whom were kept under active surveillance, was analyzed. The study reported that metastasis-directed therapy improved both biochemical-free and androgen deprivation therapy-free survival in comparison with active surveillance. This interview took place at the virtual European Association of Urology (EAU) Virtual Meeting 2021.